Rhythm Pharmaceuticals (RYTM) Competitors $56.23 -3.54 (-5.92%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RYTM vs. MORF, ARVN, PLRX, ANNX, TBPH, GMAB, SMMT, RDY, PCVX, and CTLTShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Morphic (MORF), Arvinas (ARVN), Pliant Therapeutics (PLRX), Annexon (ANNX), Theravance Biopharma (TBPH), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Catalent (CTLT). These companies are all part of the "medical" sector. Rhythm Pharmaceuticals vs. Morphic Arvinas Pliant Therapeutics Annexon Theravance Biopharma Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Vaxcyte Catalent Rhythm Pharmaceuticals (NASDAQ:RYTM) and Morphic (NASDAQ:MORF) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Do insiders and institutionals have more ownership in RYTM or MORF? 94.3% of Morphic shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 25.6% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, RYTM or MORF? Rhythm Pharmaceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Does the MarketBeat Community prefer RYTM or MORF? Rhythm Pharmaceuticals received 210 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 66.51% of users gave Rhythm Pharmaceuticals an outperform vote while only 57.35% of users gave Morphic an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes28866.51% Underperform Votes14533.49% MorphicOutperform Votes7857.35% Underperform Votes5842.65% Which has stronger valuation and earnings, RYTM or MORF? Morphic has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Morphic is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$77.43M44.63-$184.68M-$4.33-12.99Morphic$520K5,490.11-$152.10M-$3.50-16.28 Do analysts rate RYTM or MORF? Rhythm Pharmaceuticals presently has a consensus price target of $62.30, suggesting a potential upside of 10.79%. Morphic has a consensus price target of $54.25, suggesting a potential downside of 4.81%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Morphic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Morphic 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is RYTM or MORF more profitable? Morphic has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Morphic's return on equity of -26.62% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Morphic N/A -26.62%-25.74% Does the media prefer RYTM or MORF? In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than Morphic. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 0 mentions for Morphic. Rhythm Pharmaceuticals' average media sentiment score of 0.00 beat Morphic's score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Rhythm Pharmaceuticals Neutral Morphic Neutral SummaryRhythm Pharmaceuticals beats Morphic on 10 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.46B$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-12.9910.92101.9117.46Price / Sales44.63244.561,195.1369.04Price / CashN/A53.4941.0436.36Price / Book312.399.306.345.87Net Income-$184.68M$154.14M$119.64M$225.66M7 Day Performance-16.49%-9.47%-5.13%-1.34%1 Month Performance10.19%-7.30%-2.72%1.15%1 Year Performance66.26%28.21%31.10%24.02% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.7757 of 5 stars$56.23-5.9%$62.30+10.8%+73.2%$3.46B$77.43M-12.99140Insider SellingMORFMorphic1.0621 of 5 stars$56.99flat$54.25-4.8%+146.6%$2.85B$520,000.00-16.28100ARVNArvinas2.1661 of 5 stars$22.48-9.8%$60.00+166.9%+8.1%$1.54B$78.50M-4.81445Short Interest ↓PLRXPliant Therapeutics3.7369 of 5 stars$12.43-3.3%$40.57+226.4%-7.9%$756.42M$1.58M-3.7290ANNXAnnexon2.6922 of 5 stars$6.12-3.3%$15.80+158.2%+139.1%$646.58MN/A-4.9860Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageTBPHTheravance Biopharma1.9899 of 5 stars$9.52-0.5%$13.75+44.4%-7.5%$465.72M$57.42M-9.43359Earnings ReportNews CoverageGMABGenmab A/S4.4263 of 5 stars$20.59-2.8%$45.20+119.5%-35.6%$13.63B$19.84B19.992,204Short Interest ↑SMMTSummit Therapeutics2.1933 of 5 stars$18.31-5.9%$34.75+89.8%+884.4%$13.50B$700,000.00-65.39105Gap UpRDYDr. Reddy's Laboratories1.3454 of 5 stars$14.17-0.5%$17.00+20.0%+6.7%$11.83B$299.87B22.6427,048Analyst DowngradeShort Interest ↑PCVXVaxcyte3.3295 of 5 stars$86.83-6.3%$147.50+69.9%+73.3%$10.82BN/A-18.88160News CoverageHigh Trading VolumeCTLTCatalent2.8783 of 5 stars$59.10+0.3%$63.40+7.3%+48.7%$10.73B$4.38B-26.1516,900Analyst UpgradeInsider SellingNews Coverage Related Companies and Tools Related Companies Morphic Competitors Arvinas Competitors Pliant Therapeutics Competitors Annexon Competitors Theravance Biopharma Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Vaxcyte Competitors Catalent Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RYTM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts